NewGenIvf Group reports total gain from IP acquisition of $17.9M for FY25

NewGenIvf Group (NIVF) received an independent valuation report from a Big Four global accounting firm of its recently acquired advanced cytometry intellectual property, the acquisition of which was initially announced on July 29, 2025. The Report sets the fair value of the IP at $17.9M. Together with the fair value of the advanced cytometry equipment and other assets obtained from this acquisition, the transaction has resulted in an immediate Bargain Purchase Gain for the Company of $19.2M and boosted the Net Asset Value of the Company by about $8.9 per share as of the date of this announcement. This gain is expected to significantly enhance the Company’s net profit in its year-end financial results. The IP is associated with the advanced cytometry technology equipment also acquired by the Company as part of the recent acquisition. This marks a transformative strategic pivot for NewGen, transitioning the Company from its existing traditional IVF services operations to becoming a technology-driven service provider. By leveraging this cutting-edge, patent-protected platform, NewGen expects to generate high-margin, recurring revenue through a capital-light business model. This includes licensing the technology, collecting royalty fees, and supplying proprietary consumables to fertility service clinics. This strategy empowers partner fertility service providers with exclusive, technology-backed solutions but no upfront investment to enhance their service offerings and clinical outcomes. To solidify its position as a technology leader in the fertility services industry, NewGen is actively pursuing all necessary regulatory approvals/clearance to ensure a seamless path to commercialization. Concurrently, NewGen will establish an in-house research and development team dedicated to advancing innovative solutions and maintaining its competitive edge. This pivot creates a protected blue ocean for growth, establishing a new, scalable path for expansion.